Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes

Cytogenetic and Genome Research

Volumn 150, Issue 3-4, 2017, Pages 194-207

  Penna, Gustavo C ^a,c   Vaisman, Fernanda ^a,b   Vaisman, Mario ^a   Sobrinho Simões, Manuel ^d,e,f,g   Soares, Paula ^d,e,f  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c Hospital Mater Dei SA   (Brazil)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

^f University of Porto   (Portugal)

^g HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

BRAF Genetics RAS TERT Thyroid cancer TP53

Indexed keywords

AKT1 PROTEIN; B RAF KINASE; MOLECULAR MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN; PROTEIN P53; PROTEIN RET; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER; UNCLASSIFIED DRUG; GENETIC MARKER;

CANCER GENETICS; CANCER MORTALITY; CANCER PROGNOSIS; CARCINOGENESIS; DISEASE SPECIFIC MORTALITY; DISTANT METASTASIS; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SYSTEMATIC REVIEW (TOPIC); THYROID CARCINOMA; THYROID FOLLICULAR CELL; GENETIC MARKER; GENETICS; MUTATION; PATHOLOGY; THYROID TUMOR;

CARCINOGENESIS; GENETIC MARKERS; HUMANS; MUTATION; THYROID NEOPLASMS;

EID: 85014065825     PISSN: 14248581     EISSN: 1424859X     Source Type: Journal    
DOI: 10.1159/000456576     Document Type: Review

References (143)

1. Armstrong MJ, Yang H, Yip L, Ohori NP, McCoy KL, et al. PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid 24:1369-1374 (2014).
2. Asa SL, Giordano TJ, LiVolsi VA: Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid 25:1-2 (2015).
3. Asioli S, Erickson LA, Righi A, Jin L, Volante M, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol 23:1269-1278 (2010a).
4. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 34:44-52 (2010b).
5. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19-23 (2000).
6. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905 (2010).
7. Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676-690 (2014).
8. Capezzone M, Marchisotta S, Cantara S, Pacini F: Telomeres and thyroid cancer. Curr Genomics 10:526-533 (2009).
9. Cardis E, Howe G, Ron E, Bebeshko V, Bogdanova T, et al. Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot 26:127-140 (2006).
10. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, et al. PAX8-PPAR γ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213-220 (2006).
11. Chen JH, Faquin WC, Lloyd RV, Nose V: Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol 24:739-749 (2011).
12. V600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol 11:291 (2013).
13. Cifuentes-Rojas C, Shippen DE: Telomerase regulation. Mutat Res 730:20-27 (2012).
14. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627 (2003).
15. Cong YS, Wen J, Bacchetti S: The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8:137-142 (1999).
16. Corapcioglu D, Sak SD, Delibasi T, Tonyukuk V, Kamel N, et al. Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas. J Transl Med 4:28 (2006).
17. Crescenzi A, Trimboli P, Modica DC, Taffon C, Guidobaldi L, et al. Preoperative assessment of TERT promoter mutation on thyroid core needle biopsies supports diagnosis of malignancy and addresses surgical strategy. Horm Metab Res 48:157-162 (2016).
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature 417:949-954 (2002).
19. Davies L, Welch HG: Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317-322 (2014).
20. de Vries MM, Celestino R, Castro P, Eloy C, Maximo V, et al. RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. Histopathology 61:833-843 (2012).
21. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17:375-381 (1993).
22. Doherty I, Sharma N: Aligning the use of portfolios with digital badging. Br J Hosp Med (Lond) 76:596-598 (2015).
23. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760 (1993).
24. Efeyan A, Serrano M: p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6:1006-1010 (2007).
25. V600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390-4398 (2012).
26. Eloy C, Ferreira L, Salgado C, Soares P, Sobrinho-Simoes M: Poorly differentiated and undifferentiated thyroid carcinomas. Turk Patoloji Derg 31 Suppl 1:48-59 (2015).
27. Esserman LJ, Thompson IM Jr, Reid B: Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 310:797-798 (2013).
28. Evans HL: Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol 85:77-80 (1986).
29. V600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464 (2006).
30. Fukushima M, Ito Y, Hirokawa M, Akasu H, Shimizu K, Miyauchi A: Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 33:958-962 (2009).
31. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V: TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol 172:403-413 (2015).
32. Garcia-Rostan G, Sobrinho-Simoes M: Poorly differentiated thyroid carcinoma: an evolving entity. Diagn Histopathol 17:114-123 (2011).
33. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226-3235 (2003).
34. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199-10207 (2005).
35. Garcia-Rostan G, Tallini G, Salvatore G: Anaplastic thyroid carcinoma: molecular tools for diagnosis and therapy. Int J Endocrinol 2015:341725 (2015).
36. George JR, Henderson YC, Williams MD, Roberts DB, Hei H, et al. Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. J Clin Endocrinol Metab 100:E1550-E1559 (2015).
37. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA: Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 139:1164-1170 (2013).
38. Handkiewicz-Junak D, Czarniecka A, Jarzab B: Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 322:8-28 (2010).
39. Hannallah J, Rose J, Guerrero MA: Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma. Int J Endocrinol 2013:317487 (2013).
40. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1-133 (2016).
41. Henderson M, Simeon-Dubach D, Albert M: Finding the path to biobank sustainability through sound business planning. Biopreserv Biobank 13:385-386 (2015).
42. Henke LE, Pfeifer JD, Ma C, Perkins SM, DeWees T, et al. BRAF mutation is not predictive of long-Term outcome in papillary thyroid carcinoma. Cancer Med 4:791-799 (2015).
43. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 339:959-961 (2013).
44. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, et al. Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 18:3566-3571 (2011).
45. Howell GM, Hodak SP, Yip L: RAS mutations in thyroid cancer. Oncologist 18:926-932 (2013).
46. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-959 (2013).
47. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371 (1992).
48. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi Y, et al. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 84:526-531 (1993).
49. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97 (2009).
50. Ivanova R, Soares P, Castro P, Sobrinho-Simoes M: Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch 440:418-424 (2002).
51. Jang EK, Song DE, Sim SY, Kwon H, Choi YM, et al. NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma. Thyroid 24:1275-1281 (2014).
52. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC: Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12:22-27 (1988).
53. Jung CK, Choi YJ, Lee KY, Bae JS, Kim HJ, et al. The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid 19:905-913 (2009).
54. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021-6026 (2013).
55. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015 (1994).
56. V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773 (2012).
57. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364-368 (2006).
58. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457 (2003).
59. Kleer CG, Giordano TJ, Merino MJ: Squamous cell carcinoma of the thyroid: an aggressive tumor associated with tall cell variant of papillary thyroid carcinoma. Mod Pathol 13:742-746 (2000).
60. V600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42:404-410 (2012).
61. V600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253:854-860 (2009).
62. Lam AK, Lo CY: Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13:176-181 (2006).
63. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-E1566 (2013).
64. Lane D, Levine A: p53 research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2:a000893 (2010).
65. Lee JH, Lee ES, Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38-46 (2007).
66. V600E mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16:240-245 (2009).
67. Leung AK, Chow SM, Law SC: Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope 118:32-38 (2008).
68. Levine AJ, Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749-758 (2009).
69. Li C, Lee KC, Schneider EB, Zeiger MA: BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97:4559-4570 (2012).
70. Li F, Chen G, Sheng C, Gusdon AM, Huang Y, et al. BRAF V600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer 22:159-168 (2015).
71. Lim DJ, Baek KH, Lee YS, Park WC, Kim MK, et al. Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 17:883-888 (2007).
72. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM: The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294-3300 (2010).
73. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, et al. The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33:4978-4984 (2014).
74. Liu X, Bishop J, Shan Y, Pai S, Liu D, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20:603-610 (2013).
75. Liu X, Qu S, Liu R, Sheng C, Shi X, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99:E1130-E1136 (2014a).
76. V600E mutation and pathological features in PTC. Eur Arch Otorhinolaryngol 271:3041-3052 (2014b).
77. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, et al. Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952 (2002).
78. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99:E754-E765 (2014).
79. Melo M, da Rocha AG, Vinagre J, Sobrinho-Simoes M, Soares P: Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis? J Clin Oncol 33:667-668 (2015).
80. Moreno Egea A, Rodriguez Gonzalez JM, Sola Perez J, Soria Cogollos T, Parrilla Paricio P: Prognostic value of the tall cell variety of papillary cancer of the thyroid. Eur J Surg Oncol 19:517-521 (1993).
81. Morita N, Ikeda Y, Takami H: Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg 32:2617-2622 (2008).
82. Motosugi U, Murata S, Nagata K, Yasuda M, Shimizu M: Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid 19:535-537 (2009).
83. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol 399:288-295 (2015).
84. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397 (2003).
85. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, et al. High frequency of telomerase reverse-Transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218 (2013).
86. Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16 (2002).
87. Nikiforov YE: Radiation-induced thyroid cancer: what we have learned from Chernobyl. Endocr Pathol 17:307-317 (2006).
88. Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7:569-580 (2011).
89. Nikiforov YE, Nikiforova MN, Gnepp DR, Fagin JA: Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene 13:687-693 (1996).
90. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV: Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 25:1478-1484 (2001).
91. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2:1023-1029 (2016).
92. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404 (2003).
93. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE: Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 98:E1852-E1860 (2013).
94. Ostrowski ML, Merino MJ: Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964-974 (1996).
95. Pavelic K, Dedivitis RA, Kapitanovic S, Cacev T, Guirado CR, et al. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Mutat Res 599:45-57 (2006).
96. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R: Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212 (2013).
97. Pillai S, Gopalan V, Smith RA, Lam AK: Diffuse sclerosing variant of papillary thyroid carcinoma-an update of its clinicopathological features and molecular biology. Crit Rev Oncol Hematol 94:64-73 (2015).
98. Pilotti S, Collini P, Del Bo R, Cattoretti G, Pierotti MA, Rilke F: A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 18:1054-1064 (1994).
99. Pita JM, Figueiredo IF, Moura MM, Leite V, Cavaco BM: Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J Clin Endocrino Metab 99:E497-E507 (2014).
100. Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, et al. Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 30:1302-1317 (2011).
101. Preto A, Cameselle-Teijeiro J, Moldes-Boullosa J, Soares P, Cameselle-Teijeiro JF, et al. Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. Mod Pathol 17:819-826 (2004).
102. Putti TC, Bhuiya TA: Mixed columnar cell and tall cell variant of papillary carcinoma of thyroid: a case report and review of the literature. Pathology 32:286-289 (2000).
103. Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr Relat Cancer 22:901-908 (2015).
104. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103:2261-2268 (2005).
105. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA 110:17426-17431 (2013).
106. Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V: A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid 21:383-389 (2011).
107. Reis-Filho JS, Preto A, Soares P, Ricardo S, Cameselle-Teijeiro J, Sobrinho-Simoes M: p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. Mod Pathol 16:43-48 (2003).
108. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893 (2009).
109. Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid 22:575-584 (2012).
110. Rosario PW, Ward LS, Carvalho GA, Graf H, Maciel RM, et al. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Arq Bras Endocrinol Metabol 57:240-264 (2013).
111. Rosario PW, Penna GC, Calsolari MR: Noninvasive encapsulated follicular variant of papillary thyroid carcinoma: is lobectomy sufficient for tumours ≥1 cm? Clin Endocrinol (Oxf) 81:630-632 (2014).
112. Rüter A, Dreifus J, Jones M, Nishiyama R, Lennquist S: Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. Surgery 120:1046-1050 (1996).
113. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A: BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 97: E1745-E1749 (2012).
114. Sarne DH: A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab 97:3094-3096 (2012).
115. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 25:1729-1735 (2004).
116. Shi X, Liu R, Qu S, Zhu G, Bishop J, et al. Association of TERT promoter mutation 1, 295, 228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab 100:E632-E637 (2015).
117. Shrestha RT, Karunamurthy A, Amin K, Nikiforov YE, Caramori ML: Multiple mutations detected preoperatively may predict aggressive behavior of papillary thyroid cancer and guide management-a case report. Thyroid 25:1375-1378 (2015).
118. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580 (2003).
119. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 444:572-576 (2004).
120. Soares P, Lima J, Preto A, Castro P, Vinagre J, et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics 12:609-617 (2011).
121. Sobrinho-Simoes M, Sambade C, Fonseca E, Soares P: Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol 10:123-131 (2002).
122. Sobrinho-Simoes M, Maximo V, Rocha AS, Trovisco V, Castro P, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 37:333-362 (2008).
123. Song YS, Lim JA, Choi H, Won JK, Moon JH, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 122:1370-1379 (2016).
124. Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB, Asa SL: Oncogene profile of papillary thyroid carcinoma. Surgery 125:46-52 (1999).
125. Tavares C, Melo M, Cameselle-Teijeiro JM, Soares P, Sobrinho-Simoes M: Endocrine tumours: genetic predictors of thyroid cancer outcome. Eur J Endocrinol 174:R117-126 (2016).
126. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 84:4232-4238 (1999).
127. Trimboli P, Nasrollah N, Amendola S, Crescenzi A, Guidobaldi L, et al. A cost analysis of thyroid core needle biopsy vs. diagnostic surgery. Gland Surg 4:307-311 (2015).
128. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589-595 (2005).
129. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M: BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 91:274-286 (2012).
130. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185 (2013).
131. Vinagre J, Pinto V, Celestino R, Reis M, Populo H, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch 465:119-133 (2014).
132. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100:950-957 (2004).
133. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31:1256-1264 (2007).
134. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262 (2005).
135. Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762 (2007).
136. Xing M: Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93 (2010).
137. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501 (2013).
138. Xing M, Liu R, Liu X, Murugan AK, Zhu G, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32:2718-2726 (2014).
139. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33:42-50 (2015).
140. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567 (2003).
141. Zafon C, Obiols G, Castellvi J, Tallada N, Baena JA, et al. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology 50:225-231 (2007).
142. V600E mutational status of 977 cases. Ann Surg Oncol 20:2266-2273 (2013).
143. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE: Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-77 (2003).